Gilead and Genesis deployed the GEMS platform to find small molecules against targets that lack training data.
Many protein targets lack enough data for standard machine learning. Genesis uses its GEMS platform to generate and optimize small molecules against Gilead-selected targets, and Gilead gets exclusive clinical development and commercialization rights. Terms include $35 million upfront across three targets, milestones and tiered royalties.
Genesis Therapeutics (Genesis Molecular AI) is an AI small-molecule discovery company whose GEMS platform and Pearl model support partnerships with Gilead and Incyte.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Published by Genesis Therapeutics (Genesis Molecular AI) on its own site — read the original case study on gilead.com ↗
Related use cases
- 01Incyte and Genesis expanded their collaboration to at least five new targets, with Incyte data used to train GEMS.
- 02Genesis reported that its Pearl system beat six cofolding models on an OpenBind protease benchmark.
- 03Genesis introduced Pearl, a generative 3D foundation model for protein-ligand structure prediction.
- 04OpenAI's dedicated healthcare vertical page/launch post.
- 05Frontier reasoning model built for biology, drug discovery and translational medicine; named qualified customers include Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.
- 06follow-up update to the life-sciences model.